Cumberland Pharmaceuticals Inc.
cumberlandpharma.comWhat Do They Do?
Sells branded prescription medicines through pharmaceutical wholesalers to health care providers and pharmacies, and develops drug candidates for serious diseases.
10-K for FY2025, filed Mar 9, 2026Cumberland Pharmaceuticals Inc. ("Cumberland," the "Company," or as used in the context of "we," "us" or "our"), is a specialty…View ↗
Our primary target markets are hospital acute care, gastroenterology and oncology. These medical specialties are characterized by…View ↗
Like many pharmaceutical companies, we engage a third-party with appropriate facilities and logistical expertise to support the U.S.…View ↗
In addition to these commercial brands, we have announced breakthrough results in a clinical study of our ifetroban product candidate in…View ↗
How Do They Make Money?
Most revenue comes from sales of branded medicines; wholesalers typically pay after shipment. Other revenue includes licensing payments and royalties, contract and grant income, and lease income.
10-K for FY2025, filed Mar 9, 2026Our revenue is derived primarily from the product sales of our FDA approved pharmaceutical brands. Revenue from sales of products is…View ↗
The Company has agreements with international partners for commercialization of the Company’s products with associated payments included in…View ↗
Other revenues also includes lease income generated by CET’s Life Sciences Center. It is a research facility that provides scientists with…View ↗
-
10-K for FY2025, filed Mar 9, 2026
FY2025 revenue by product or service ↗
$44.5M
-
10-K for FY2025, filed Mar 9, 2026
$44.5M ↗
| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Product
Sold outright
10-K for FY2025, filed Mar 9, 2026 |
91%
FY2022: 97%
|
Product, FY2025
$40.4M Sources
|
Sold outright |
|
Other
Mix
|
9.3%
FY2022: 3.2%
|
Other, FY2025
$4.1M Sources
|
Mix |
Who Are Their Customers?
U.S. pharmaceutical wholesalers are the primary buyers; they supply products to hospitals, clinics and retail pharmacies. International partners handle registration, distribution and sales in their territories.
10-K for FY2025, filed Mar 9, 2026Our primary customers are wholesale pharmaceutical distributors in the United States. Total revenue by customer for each customer…View ↗
Like many pharmaceutical companies, we engage a third-party with appropriate facilities and logistical expertise to support the U.S.…View ↗
The Company has agreements with international partners for commercialization of the Company’s products with associated payments included in…View ↗
10-K for FY2025, filed Mar 9, 2026
2025 Customer 1 27% Customer 2 25% Customer 3 22%View ↗
Do Revenues Turn Into Profits?
Not on paper. It lost $2.8M in FY2025, but brought in more cash than it spent: $4.8M of free cash flow.
10-K for FY2025, filed Mar 9, 2026
−$2.8MView ↗
10-K for FY2025, filed Mar 9, 2026
−$2.8MView ↗
10-K for FY2025, filed Mar 9, 2026
$4.8MView ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 7, 2026
−$4.3MView ↗
- ▲ +477% (Loss)
- vs −$740.7K in Q2 FY2025
-
Aug 4, 2026
Sold its FDA-approved brands to Apotex
Apotex paid $100 million at closing; Cumberland retained its development pipeline and majority ownership in Cumberland Emerging Technologies.
Sources
8-K, filed Aug 4, 2026
During the second quarter, Cumberland completed a transaction with Apotex Health, the largest Canadian pharmaceutical company, to integrate…View ↗
Growing. Revenue grew 24% in 4 years, from $36M in FY2021 to $44.5M in FY2025, about 5% a year.
H. pylori product
The newer portfolio lists Talicia for H. pylori infection, while the earlier portfolio listed Omeclamox-Pak for that indication.
10-K for FY2022, filed Mar 13, 2023 10-K for FY2025, filed Mar 9, 2026Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor® (ibuprofen) injection, for the treatment of…View ↗
Acetadote® (acetylcysteine) injection, for the treatment of acetaminophen poisoning; Caldolor® (ibuprofen) injection, for the treatment of…View ↗
Who Do They Compete With?
Competes with Geneva Pharmaceuticals, Hikma Pharmaceuticals, Roxane Laboratories, InnoPharma, Hospira, Mallinckrodt, Heron Therapeutics, Trevena, Pacira Pharmaceuticals, Vertex Pharmaceuticals, RedHill Biopharma, Allergan, Ironwood Pharmaceuticals, Synergy Pharmaceuticals, Braintree Laboratories, Merck, Tesaro, GSK, Par Pharmaceuticals, and Roche Pharmaceuticals
10-K for FY2025, filed Mar 9, 2026Acetadote is our injectable formulation of N-acetylcysteine (“NAC”) for the treatment of acetaminophen overdose. NAC is accepted worldwide…View ↗
Loading...
